B&K (HKSE:02396) FCF Margin %: 0.00% (As of Dec. 2025)


HKSE:02396 B&K Corp Ltd HKSE:02396
8 GF Score
Price HK$3.89
! 1 Warning Sign
View Full Analysis

What is B&K FCF Margin %?

B&K HKSE:02396 -0.26% 8 FCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates HKSE:02396 with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 948 Biotechnology companies, B&K ranks worse than 87.97% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. B&K's Free Cash Flow for the three months ended in Dec. 2025 was HK$0.00 Mil. B&K's Revenue for the three months ended in Dec. 2025 was HK$0.58 Mil. Therefore, B&K's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, B&K's current FCF Yield % is -4.63%.

The historical rank and industry rank for B&K's FCF Margin % or its related term are showing as below:

HKSE:02396' s FCF Margin % Range Over the Past 10 Years
Min: -39876.7   Med: -16071.06   Max: -3670.36
Current: -3670.36

During the past 3 years, the highest FCF Margin % of B&K was -3670.36%. The lowest was -39876.70%. And the median was -16071.06%.

HKSE:02396's FCF Margin % is ranked worse than
87.97% of 948 companies
in the Biotechnology industry
Industry Median: -81.28 vs HKSE:02396: -3670.36

B&K FCF Margin % Related Terms

B&K FCF Margin % Historical Data

* Premium members only.

The historical data trend for B&K's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

B&K FCF Margin % Chart

B&K Annual Data
Trend Dec23 Dec24 Dec25
FCF Margin %
-12,944.38 -39,876.70 -16,071.06

B&K Quarterly Data
Dec23 Dec24 May25 Sep25 Dec25
FCF Margin % 0.00 -7,590.68 0.00 0.00 0.00

HKSE:02396 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, B&K's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

B&K FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, B&K's FCF Margin % distribution charts can be found below:

* The bar in red indicates where B&K's FCF Margin % falls into.


HKSE:02396
8GF Score
B&K Corp Ltd HKSE:02396
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

B&K FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

B&K's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-92.73/0.577
=-16,071.06 %

B&K's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=0/0.577
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
B&K (HKSE:02396) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on B&K and its competitors. According to the industry distribution chart, B&K ranks #834 out of 948 companies in the Biotechnology industry, placing it in the top 88%.
Is B&K's FCF Margin % too high?
B&K's current FCF Margin % is 0.00%. Based on the distribution chart, B&K ranks #834 out of 948 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, B&K has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does B&K's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, B&K ranks #834 out of 948 companies for FCF Margin %. This places B&K in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on B&K and its competitors. B&K's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is B&K stock overvalued right now?
B&K (HKSE:02396) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. B&K's overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For B&K (HKSE:02396), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

B&K Business Description

Address No. 19 Qinling Road, Xiexin Center, Room 1507, Building 1, Laoshan District, Shandong Province, Qingdao, CHN
B&K Corp Ltd is a China-based biopharmaceutical company committed to developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities. The company prominently focuses on the discovery, development and commercialization of therapies for wound healing, currently PDGF drugs. Its pipeline consisted of ten candidates, seven of which are PDGF candidates, including two Core Products, namely Pro-101-1 for the treatment of thermal burns and Pro-101-2 for the treatment of DFUs, which are rhPDGF-BB drugs. The company operates in a single reportable segment: the research and development of biopharmaceutical products. Geographically, the company generates all its revenue from Chinese Mainland.
8GF Score

Get the complete analysis for HKSE:02396

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.89
Price